Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy
Krebs, Matthew G Branson, A. Barber, S. Poile, C. King, A. Greystoke, A. Moody, S. Nolan, L. Scotland, M. Darlison, L.
Krebs, Matthew G
Branson, A.
Barber, S.
Poile, C.
King, A.
Greystoke, A.
Moody, S.
Nolan, L.
Scotland, M.
Darlison, L.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Krebs MG, Branson A, Barber S, Poile C, King A, Greystoke A, et al. Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003590.